This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
ISRG's Ion Platform Procedure Grows 52%: Can This Trend Continue?
by Indrajit Bandyopadhyay
Intuitive Surgical's Ion platform saw Q2 procedures jump 52% to 35,000, expanding globally as utilization rises despite softer system placements.
SYKPositive Net Change ISRGNegative Net Change GMEDPositive Net Change
medical medical-devices
Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength
by Moumi Mondal
HOLX targets a mid-single-digit organic growth rebound in 2026, powered by Breast Health recovery and new product innovation.
HOLXPositive Net Change MMSINegative Net Change GEHCNegative Net Change
medical medical-devices
Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
by Zacks Equity Research
GMED posts strong Q2 with earnings and revenues, boosted by the Nevro acquisition and expanded margins.
BSXPositive Net Change GMEDPositive Net Change MEDPPositive Net Change WGSPositive Net Change
earnings medical medical-devices
SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.
BSXPositive Net Change WSTPositive Net Change GEHCNegative Net Change
earnings medical medical-devices
Hims & Hers Drives the Consumer-Centric Transformation in Digital Care
by Debanjana Dey
HIMS leverages its consumer-first telehealth model, AI-driven personalization and global expansion plans to outpace industry growth.
TDOCNegative Net Change HIMSNegative Net Change DOCSNegative Net Change
medical medical-devices
Reasons to Add Veeva Systems Stock to Your Portfolio for Now
by Zacks Equity Research
VEEV's strong first quarter, product innovations and strategic deals drive growth prospects despite rising costs.
BSXPositive Net Change WSTPositive Net Change VEEVPositive Net Change MEDPPositive Net Change
medical medical-devices
CAH Q4 Earnings Beat Estimates, '26 EPS View Up, Stock Falls
by Zacks Equity Research
Cardinal Health's fourth-quarter fiscal 2025 results benefit from solid Medical and Other segments' revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
BSXPositive Net Change CAHPositive Net Change WSTPositive Net Change MEDPPositive Net Change
earnings medical medical-devices
Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
RAPTNo Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up
by Zacks Equity Research
Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.
BSXPositive Net Change MEDPPositive Net Change WGSPositive Net Change
earnings medical medical-devices
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise
by Zacks Equity Research
PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.
BSXPositive Net Change PODDNegative Net Change MEDPPositive Net Change WGSPositive Net Change
earnings medical medical-devices